Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins sold 5,039 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $7.16, for a total transaction of $36,079.24. Following the sale, the chief financial officer directly owned 104,719 shares of the company’s stock, valued at approximately $749,788.04. The trade was a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Daniel Calkins also recently made the following trade(s):

• On Wednesday, December 24th, Daniel Calkins sold 80 shares of Verastem stock. The stock was sold at an average price of $7.86, for a total transaction of $628.80.

Verastem Stock Down 5.7%

NASDAQ:VSTM traded down $0.41 on Wednesday, reaching $6.79. The stock had a trading volume of 1,969,071 shares, compared to its average volume of 2,464,841. The company has a 50-day moving average of $8.71 and a 200 day moving average of $8.10. The company has a current ratio of 2.58, a quick ratio of 2.55 and a debt-to-equity ratio of 2.06. The stock has a market cap of $453.41 million, a P/E ratio of -1.68 and a beta of 0.44. Verastem, Inc. has a 12-month low of $4.01 and a 12-month high of $11.24.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.84). The company had revenue of $11.24 million during the quarter, compared to analyst estimates of $5.76 million. On average, research analysts predict that Verastem, Inc. will post -3.02 earnings per share for the current year.

Institutional Investors Weigh In On Verastem

Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in Verastem by 236.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 756,402 shares of the biopharmaceutical company’s stock worth $4,561,000 after buying an additional 531,873 shares during the last quarter. Squarepoint Ops LLC grew its position in Verastem by 2,995.6% in the 2nd quarter. Squarepoint Ops LLC now owns 351,569 shares of the biopharmaceutical company’s stock worth $1,459,000 after purchasing an additional 340,212 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Verastem in the second quarter valued at approximately $106,000. Panagora Asset Management Inc. bought a new stake in shares of Verastem during the second quarter valued at approximately $550,000. Finally, Armistice Capital LLC acquired a new position in shares of Verastem during the second quarter worth approximately $8,864,000. Institutional investors own 88.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Verastem in a research report on Wednesday, October 8th. Guggenheim reiterated a “buy” rating on shares of Verastem in a research note on Tuesday, December 30th. Mizuho set a $15.00 price objective on shares of Verastem in a report on Wednesday, October 29th. Wall Street Zen downgraded shares of Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald raised shares of Verastem to a “strong-buy” rating in a research report on Thursday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.29.

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.